Aripiprazole: Review of its Pharmacology and Therapeutic Use in Psychiatric Disorders

References

• Ayd FJJ: A survey of neuroleptic-induced extrapyram-idal reactions. JAMA 1961; 175:1054–1061.
   PubMed Web of Science ®Google Scholar
• Rupniak NMJ, Jenner P. Marsden CD: Acute dystonia induced by neuroleptic drugs. Psychopharmacol 1986; 88:403–419.
   PubMed Web of Science ®Google Scholar
• Van Putten T: The many faces of akathisia. Compre-hensive Psychiatry 1975; 16:43–47.
   Google Scholar
• Van Putten T, May PRA, Marder SR: Why do schizo-phrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31:67–72.
   PubMed Web of Science ®Google Scholar
• Kane JM, Smith JM: Tardive dyskinesia: Prevalence and risk factors, 1959-1979. Arch Gen Psychiatry 1982; 39:473–481.
   PubMed Web of Science ®Google Scholar
• Jeste DV, Wyatt RJ: Understanding and treating Tardive Dyskinesia. New York: Guilford Press; 1982.
   Google Scholar
• Kane JM: Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview. Br J Psychiatry 1992; 160\(supp1.17):41–45.
   Google Scholar
• Krupp P, Barnes P: Clozapine-associated agranulo-cyto sis: Risk and aetiology. Br J Psychiatry 1992; 160 (suppl. 17): 38–40.
   Google Scholar
• Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Brier A, Tollefson GD. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperi-dol. The Canadian Collaborative Group for research in schizophrenia. Archives of General Psychiatry 2000; 57:249–258.
   PubMed Web of Science ®Google Scholar
• Lahti AC, Weiler MA, Corey PK, et al. Antipsychotic properties of the partial dopamine agonist (-)-3(3-hydroxy-pheny1)-N-n-propylpiperidine (preclamol) in schizo-phrenia. Biol Psychiatry 1998; 43:2–11.
   PubMed Web of Science ®Google Scholar
• Sramek JJ, Eldon MA, Posvar E, et al. Initial safety, tolerability, pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia. Psychophar-macol Bull 1998; 34:93–99.
   Google Scholar
• Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affmity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302:381–389.
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT lA receptor. Eur J Pharmacol 2002; 441:137–140.
   PubMed Web of Science ®Google Scholar
• McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T. Aripiprazole: A dopamine-serotonin system stabilizer. Int J Neuropsychopharma-col 2002; 5(Suppl 1):5176.
   Google Scholar
• AbilifyTM prescribing information. Bristol-Myers Squibb Company, Princeton, New Jersey; November 2002.
   Google Scholar
• Goodnick and Jerry. Expert Opin Pharmacother 2002; 3:1773–1781.
   Google Scholar
• Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neu-ropsychopharmacol 1999; 20:612–627.
   Google Scholar
• Inoue A, Nakata Y. Strategy for modulation of central dopamine transmission based on partial agonist concept in schizophrenia. Jpn J Pharmacol 2001; 86:376–380.
   PubMedGoogle Scholar
• Grunder G, Carlsson A, Wong D. Mechanism of action of new antipsychotic medications. Arch Gen Psychiatry 2003; 60:974–977.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Tottori K, Uwahodo Y, et al. 7-144442,3-dichloropheny1)-1-piperazinylibutyloxyl-3,4-dihydro-2(111)-quinolinone (OPC-14597), a new putative anti-psychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagositic activity. J Pharmacol Exp Ther 1995; 274:329–336.
   PubMed Web of Science ®Google Scholar
• Jordan S, Tadori Y, McQuade R, Yocca F, Kostic D, Kikuchi T. Definitive evidence that aripiprazole is a D2 and 5-HT Li partial agonist. Presented at the 2003 APA Annual Meeting, San Francisco, CA; May 17–22,2003.
   Google Scholar
• Carson WH, Saha AR, Iwamoto T, Lin C, Kujawa MJ. Meta-analysis of prolactin effects with aripiprazole. Int J Neuropsychopharmacol 2002b; 5(Suppl 1):5186.
   Google Scholar
• Bramer S, Shoaf S, Salazar DE, Mallikaarjun S. Effects of renal and hepatic impairment on the pharmacokinet-ics of aripiprazole. Presented at the 2003 APA Annual Meeting, May 17–22,2003; San Francisco, CA.
   Google Scholar
• Cornblatt B, Kern RS, Carson WH, Ali MW, Luo X, Green M. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. Int J Neuropsychophar-macol 2002; 5(Suppl 1):5185.
   Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Arip-iprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60:681–690.
   Google Scholar
• Daniel DG, Saha AR, Ingenito G, Carson WH, Dunbar G. Aripiprazole, a novel antipsychotic: Overview of a phase II study result. Int J Neuropsychopharmacol 2000; 3(Suppl 1):S157.
   Google Scholar
• Kane JM, Carson WH, Saha A, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763–771.
   Google Scholar
• Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new atypical antipsychotic: phase II clinical trial result. Eur Neuropsychopharm 1997; 7(Suppl 2):S227.
   Google Scholar
• Lieberman J, Carson WH, Saha AR, et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia. Int J Neuropsychopharmacol 2002; 5(Suppl 1):S186.
   Google Scholar
• Carson WH, Pigott TA, Saha AR, et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. Int J Neuropsychopharmacol 2002a; 5(Suppl 1):S187.
   Google Scholar
• Kujawa M, Saha AR, Ingenito GG, et al. Aripiprazole for long-term maintenance treatment of schizophrenia. Int J Neuropsychopharmacol 2002; 5(Suppl 1):S186.
   Google Scholar
• Kane J, Carson W, Kujawa M, et al. Aripiprazole vs perphenazine in treatment-resistant schizophrenia. Pre-sented at the 2003 APA Annual Meeting, May 17–22, 2003; San Francisco, CA.
   Google Scholar
• Jody D, Marcus R, Keck P. et al. Aripiprazole vs pla-cebo in acute mania. Int J Neuropsychopharmacol 2002a; 5(Suppl 1):557.
   Google Scholar
• Keck Jr. PE, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry 2003; 160:1651–1658.
   Google Scholar
• Bristol Meyers Squibb/Otsuka America Pharmaceut-icals. Data on file.
   Google Scholar
• Marcus et al. Aripiprazole for acute mania. Presented at the 5th International Conference on Bipolar Disorder, June 11–14,2003 Pittsburgh, PA.
   Google Scholar
• Bourin M, Auby P. Swanink R, et al. Aripiprazole vs haloperidol for maintained treatment effect in acute mania. Presented at the 2003 APA Annual Meeting, May 17–22,2003; San Francisco, CA.
   Google Scholar
• Manos G, McQuade R, Stock E, et al. Long-term effects of aripiprazole on the negative symptoms of schizo-phrenia. Presented at the 2003 APA Annual Meeting, May 17–22,2003; San Francisco, CA.
   Google Scholar
• Gupta S, Frank BL, Madhusoodanan S: Tardive dyski-nesia: Legal issues and consent. Psychiatric Annals 2002; 32:245–248.
   Google Scholar
• Jody D, Saha AR, Iwamoto T, et al. Meta-analysis of weight effects with aripiprazole. In J Neuropsycho-pharmacol 2002b; 5(Suppl 1):S186.
   Google Scholar
• Marder SR, Jody D, Kaplita S, et al. Glycemic control and plasma lipids in long-term treatment with aripipra-zole. Presented at the 2003 APA Annual Meeting, May 17–22,2003; San Francisco, CA.
   Google Scholar
• Weiden P. Waldeck R, Tafesse E, Cislo P. L'Italien G, Carson W. Aripiprazole is not associated with incre-ased diabetes risk: A long-term model. Presented at the 2003 APA Annual Meeting, May 17–22, 2003; San Francisco, CA.
   Google Scholar
• Casey D, L'Italien GL, Waldeck R, Cislo P, Carson W. Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo. Presented at the 2003 APA Annual Meeting, May 17–22,2003; San Francisco, CA.
   Google Scholar
• Grundy SM, Becker D, Clark LT, et al. Executive sum-mary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Stock E, Marder SR, Saha AR, et al. Safety and tolera-bility meta-analysis of aripiprazole in schizophrenia. Int J Neuropsychopharmacol 2002a; 5(Suppl 1):S186.
   Google Scholar
• Stock E, Marder SR, Saha AR, et al. Meta-analysis of cardiac safety with aripiprazole. Int J Neuropsycho-pharmacol 2002b; 5(Suppl 1):S186.
   Google Scholar
• Schatz IJ: Orthostatic Hypotension II. Clinical diagno-sis, testing, and treatment. Arch Intern Med 1984; 144:1037–1041.
   Google Scholar
• Pollack MU, Rosenbaum JF: Management of anti-depressant-induced side effects. A practical guide for the clinician. J Clinical Psychiatry 1987; 48:3–8.
   Google Scholar
• Streim JE, McQuade RD, Stock E et al. Aripiprazole treatment of institutionalized patients with psychosis of Alzheimer 's dementia. Presented at 17 Annual meeting of the American Association of Geriatric Psychiatry, February 21–24,2004; Baltimore, MD.
   Google Scholar
• Kujawa MJ and Bristol Meyers Squibb. Safety and tolera-bility of aripiprazole in elderly patients with psychosis of Alzheimer's dementia: A pooled analysis. Presented at 17 Annual meeting of the American Association of Geriatric Psychiatry, February 21–24,2004; Baltimore, MD.
   Google Scholar